RU2012122983A - Способ лечения и профилактики острой эритемы - Google Patents
Способ лечения и профилактики острой эритемы Download PDFInfo
- Publication number
- RU2012122983A RU2012122983A RU2012122983/15A RU2012122983A RU2012122983A RU 2012122983 A RU2012122983 A RU 2012122983A RU 2012122983/15 A RU2012122983/15 A RU 2012122983/15A RU 2012122983 A RU2012122983 A RU 2012122983A RU 2012122983 A RU2012122983 A RU 2012122983A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- receptor agonist
- adrenergic receptor
- acute erythema
- alpha
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 61
- 206010015150 Erythema Diseases 0.000 title claims abstract 26
- 230000001154 acute effect Effects 0.000 title claims abstract 25
- 231100000321 erythema Toxicity 0.000 title claims abstract 25
- 230000002265 prevention Effects 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 claims abstract 16
- 239000000126 substance Substances 0.000 claims abstract 14
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims abstract 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 8
- 208000001034 Frostbite Diseases 0.000 claims abstract 6
- 208000006877 Insect Bites and Stings Diseases 0.000 claims abstract 6
- 206010042496 Sunburn Diseases 0.000 claims abstract 6
- 238000001959 radiotherapy Methods 0.000 claims abstract 6
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims abstract 5
- 230000000699 topical effect Effects 0.000 claims abstract 4
- 206010040844 Skin exfoliation Diseases 0.000 claims abstract 2
- 239000002537 cosmetic Substances 0.000 claims abstract 2
- 238000002651 drug therapy Methods 0.000 claims abstract 2
- 238000001126 phototherapy Methods 0.000 claims abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 8
- 229960003679 brimonidine Drugs 0.000 claims 8
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 5
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 229960001528 oxymetazoline Drugs 0.000 claims 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229960000337 tetryzoline Drugs 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25480509P | 2009-10-26 | 2009-10-26 | |
| US61/254,805 | 2009-10-26 | ||
| PCT/US2010/053198 WO2011053487A1 (en) | 2009-10-26 | 2010-10-19 | Methods of treating or preventing acute erythema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012122983A true RU2012122983A (ru) | 2014-01-27 |
Family
ID=43922456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012122983/15A RU2012122983A (ru) | 2009-10-26 | 2010-10-19 | Способ лечения и профилактики острой эритемы |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110224216A1 (enExample) |
| EP (1) | EP2493309A4 (enExample) |
| JP (1) | JP2013508454A (enExample) |
| KR (1) | KR20120125230A (enExample) |
| CN (1) | CN102711471A (enExample) |
| AU (1) | AU2010313643B2 (enExample) |
| BR (1) | BR112012009891A2 (enExample) |
| CA (1) | CA2779063A1 (enExample) |
| MX (1) | MX2012004890A (enExample) |
| NZ (1) | NZ600125A (enExample) |
| RU (1) | RU2012122983A (enExample) |
| WO (1) | WO2011053487A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| RU2535008C2 (ru) | 2010-03-26 | 2014-12-10 | Галдерма Ресерч Энд Девелопмент | Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии |
| MX2012010824A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| RU2587041C2 (ru) | 2010-06-30 | 2016-06-10 | Галдерма Ресерч Энд Девелопмент | Способ предотвращения или лечения опухоли кожи |
| AU2011273509A1 (en) | 2010-06-30 | 2013-06-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| SG189896A1 (en) | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| AU2012217858A1 (en) | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| EP2962689B1 (en) * | 2014-06-30 | 2018-04-11 | Galderma S.A. | Method of treating flushing associated with carcinoid tumors and carcinoid syndrome |
| CN106361733A (zh) * | 2015-07-22 | 2017-02-01 | 刘里远 | 外用经穴激动剂 |
| EP3434271B1 (en) * | 2016-03-22 | 2020-08-26 | Doris Maria Hexsel | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| FR3119986B1 (fr) * | 2021-02-19 | 2024-02-16 | Tarian Pharma | Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911196B2 (en) * | 2002-07-31 | 2005-06-28 | Samir I. Hamtini | Topical medicament for treating nappy rash |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20050226899A1 (en) * | 2004-04-08 | 2005-10-13 | Mauro Castiglioni | Cosmetic mask composition |
| CA2567401C (en) * | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| MX2012010824A (es) * | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| US20120101104A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2010
- 2010-10-19 EP EP20100827329 patent/EP2493309A4/en not_active Withdrawn
- 2010-10-19 RU RU2012122983/15A patent/RU2012122983A/ru unknown
- 2010-10-19 BR BR112012009891A patent/BR112012009891A2/pt active Search and Examination
- 2010-10-19 MX MX2012004890A patent/MX2012004890A/es unknown
- 2010-10-19 AU AU2010313643A patent/AU2010313643B2/en not_active Ceased
- 2010-10-19 KR KR1020127013737A patent/KR20120125230A/ko not_active Ceased
- 2010-10-19 CN CN2010800485638A patent/CN102711471A/zh active Pending
- 2010-10-19 CA CA2779063A patent/CA2779063A1/en not_active Abandoned
- 2010-10-19 JP JP2012536876A patent/JP2013508454A/ja active Pending
- 2010-10-19 NZ NZ60012510A patent/NZ600125A/en not_active IP Right Cessation
- 2010-10-19 WO PCT/US2010/053198 patent/WO2011053487A1/en not_active Ceased
- 2010-10-19 US US12/907,543 patent/US20110224216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120125230A (ko) | 2012-11-14 |
| EP2493309A4 (en) | 2013-05-01 |
| BR112012009891A2 (pt) | 2015-09-29 |
| AU2010313643B2 (en) | 2015-11-12 |
| CN102711471A (zh) | 2012-10-03 |
| WO2011053487A1 (en) | 2011-05-05 |
| EP2493309A1 (en) | 2012-09-05 |
| NZ600125A (en) | 2014-05-30 |
| CA2779063A1 (en) | 2011-05-05 |
| US20110224216A1 (en) | 2011-09-15 |
| MX2012004890A (es) | 2012-09-28 |
| JP2013508454A (ja) | 2013-03-07 |
| AU2010313643A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012122983A (ru) | Способ лечения и профилактики острой эритемы | |
| JP2013508454A5 (enExample) | ||
| Ibbotson et al. | Ambulatory photodynamic therapy using low irradiance inorganic light‐emitting diodes for the treatment of non‐melanoma skin cancer: an open study | |
| ES2498217T3 (es) | Composición en forma de gel basada en brimonidina | |
| Lomax et al. | Duration of action of a topical anaesthetic formulation for pain management of mulesing in sheep | |
| CA2780586C (en) | Combination therapy for treating or preventing an inflammatory skin disorder | |
| RU2013125042A (ru) | Способ предотвращения или лечения опухоли кожи | |
| Gupta et al. | New pharmacotherapy for the treatment of onychomycosis: an update | |
| WO2009053741A3 (en) | Novel formulation | |
| MX370361B (es) | Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. | |
| CA3117737A1 (en) | Method of treatment of biological surfaces | |
| Legabão et al. | The zoonosis sporotrichosis can be successfully treated by photodynamic therapy: A scoping review | |
| Friedmann et al. | Multiple sequential light and laser sources to activate aminolevulinic acid for rosacea | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| Mansouri et al. | Devices and topical agents for rosacea management | |
| Tong et al. | Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea | |
| da Costa et al. | Evaluation of activity and toxicity of combining clioquinol with ciclopirox and terbinafine in alternative models of dermatophytosis | |
| AU2012324544B2 (en) | Method for treating capillary hemangiomas | |
| JP2014530847A5 (enExample) | ||
| CA2855005A1 (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| US9744125B2 (en) | Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses | |
| US20090233914A1 (en) | Composition for treatment of nail infections | |
| CO2020007091A2 (es) | Composiciones y métodos para el tratamiento o prevención de síntomas vasomotores | |
| Fernández-Guarino et al. | Studies of methyl aminolevulinate photodynamic therapy for actinic keratosis | |
| WO2017161432A1 (pt) | Uso de uma composição farmacêutica destinada ao tratamento do eritema cutâneo das poiquilodermias |